文献
J-GLOBAL ID:201702224416211129
整理番号:17A1363220
EZH2選択的阻害剤以上の抗腫瘍効果を有する新規の経口投与可能なEZH1/2二重阻害剤
Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor
著者 (18件):
Honma Daisuke
(Oncology Laboratories, Daiichi Sankyo Co., Ltd, Tokyo, Japan)
,
Kanno Osamu
(Medicinal Chemistry Function, Asubio Pharma Co, Ltd., Kobe, Japan)
,
Watanabe Jun
(Oncology Laboratories, Daiichi Sankyo Co., Ltd, Tokyo, Japan)
,
Kinoshita Junzo
(Medicinal Safety Research Laboratories, Daiichi Sankyo Co., Ltd, Tokyo, Japan)
,
Hirasawa Makoto
(Drug Metabolism & Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd, Tokyo, Japan)
,
Nosaka Emi
(Oncology Laboratories, Daiichi Sankyo Co., Ltd, Tokyo, Japan)
,
Shiroishi Machiko
(Oncology Laboratories, Daiichi Sankyo Co., Ltd, Tokyo, Japan)
,
Takizawa Takeshi
(Biological Research Department, Daiichi Sankyo RD Novare Co., Ltd, Tokyo, Japan)
,
Yasumatsu Isao
(Biological Research Department, Daiichi Sankyo RD Novare Co., Ltd, Tokyo, Japan)
,
Horiuchi Takao
(Oncology Laboratories, Daiichi Sankyo Co., Ltd, Tokyo, Japan)
,
Nakao Akira
(End-Organ Disease Laboratories, Daiichi Sankyo Co., Ltd, Tokyo, Japan)
,
Suzuki Keisuke
(Pain & Neuroscience Laboratories, Daiichi Sankyo Co., Ltd, Tokyo, Japan)
,
Yamasaki Tomonori
(Pharmacovigilance Department, Daiichi Sankyo Co., Ltd, Tokyo, Japan)
,
Nakajima Katsuyoshi
(Venture Science Laboratories, Daiichi Sankyo Co., Ltd, Tokyo, Japan)
,
Hayakawa Miho
(Pharmacovigilance Department, Daiichi Sankyo Co., Ltd, Tokyo, Japan)
,
Yamazaki Takanori
(New Drug Regulatory Affairs Department, Daiichi Sankyo Co., Ltd, Tokyo, Japan)
,
Yadav Ajay Singh
(Daiichi Sankyo India Pharma Pvt. Ltd, Gurgaon, India)
,
Adachi Nobuaki
(Oncology Laboratories, Daiichi Sankyo Co., Ltd, Tokyo, Japan)
資料名:
Cancer Science (Web)
(Cancer Science (Web))
巻:
108
号:
10
ページ:
2069-2078
発行年:
2017年
JST資料番号:
U0505A
ISSN:
1349-7006
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
アメリカ合衆国 (USA)
言語:
英語 (EN)